Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] - The company announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, highlighting initial clinical data from the SPOTLIGHT Phase 1b/2a study [1][2] Presentation Details - The first abstract discusses initial results from the SPOTLIGHT study on briquilimab in adults with CIndU who remain symptomatic despite H-1 antihistamine treatment, scheduled for presentation on June 14 [2] - The second abstract presents findings on briquilimab's efficacy in protecting against relapse of dermatitis in a mouse model, also scheduled for June 14 [2] - The third abstract reports updated results showing briquilimab's rapid and clinically meaningful disease control in adults with CSU, to be presented on June 15 [2] - The fourth abstract focuses on briquilimab's effects on mitigating COPD-like features in an asthma model, scheduled for presentation on June 15 [2] Company Overview - Jasper is developing briquilimab as a targeted aglycosylated monoclonal antibody that inhibits signaling through the c-Kit receptor, leading to mast cell depletion and addressing inflammatory responses in mast cell driven diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU and CIndU [3]